What happens when patients with myeloma and sustained MRD negativity choose to discontinue maintenance? We sought to answer this question in our study MRD2STOP, out now in Blood Cancer Journal nature.com/articles/s4140…

Hot off the press in Blood Cancer Journal Salvage therapy for post CAR T relapse: Are BiTES the right choice? n=139 (mostly idecel), relapse <5m,>50% EMD RR:Talq (80%), Tec (65%), IMiD/PI/CD38 (30%),Other (25%) ⬆️⬆️DoR, PFS, OS w BsAb vs Others regardless of EMD, timing of relapse.

1/ Easily the most provocative #MMsm oral abstract of #ASH24 🤔 Does transplantation interfere with subsequent CAR-T efficacy? Gustine et al Andrew Yee, MD Noopur Raje Part 1 - setting the stage Why high-dose melphalan might interfere with T-cell fitness…

Join myeloma specialist Dr. Kylee Maclachlan for the presentation "Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease." 2:15 pm PST at #ASH24. Memorial Sloan Kettering Cancer Center Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 buff.ly/4f6J3gP

Out in NEJM as Thanos Dimopoulos is speaking!! 🚨 Most important #ASH24 abstract in #MMsm: AQUILA study demonstrating OS benefit with dara x3 years in high-risk SMM. Monthly dara now can prevent Dara quad & ASCT later? Will be worth it in some patients! nejm.org/doi/full/10.10…

Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24 Thanos Dimopoulos NEJM Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial nejm.org/doi/full/10.10… Slides in thread

#ASH24 📊: Daratumumab vs lenalidomide maintenance in NDMM TE+TI, 1:1 randomized IIT Memorial Sloan Kettering Cancer Center. n=87 (39 dara, 38 len). Similar (numerically ⬆️) 12mPFS, 24mPFS, >=CR & MRD- rates with fewer drug discontinuation on dara arm. 66% prior dara exposure. Urvi Shah Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰

Congrats to ⁦Rahul Banerjee, MD, FACP⁩ ⁦Vincent Rajkumar⁩ ⁦Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰⁩ ⁦Robert Z. Orlowski⁩ ⁦Shaji Kumar⁩ et al for this extremely clinically impactful paper! #mmsm ashpublications.org/blood/article/…

MSK is the first hospital in New York City to offer gene therapy for #sicklecelldisease and beta thalassemia through its pediatric program, MSK Kids. “Following our leadership in gene therapy clinical trials, this authorization expands our treatment options for these

So excited!! Welcome Urvi Shah to Fred Hutch Cancer Center Grand Rounds. I’m glad you joined by Zoom since shockingly it is raining today in Seattle for the first time in 2 weeks :) Cc Memorial Sloan Kettering Cancer Center Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Sridevi Rajeeve, MD Gunjan Shah Michael Scordo #MMsm

Looking forward to the inaugural #iwGPRC5D International Workshop on GPRC5D-Targeted Myeloma Therapies on March 22 in NYC! iwgprc5d.org/agenda/ Excited to learn & share our collective knowledge on the next frontier beyond BCMA. Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 @ShamMailankody Noopur Raje ...

Dr. Rahul Banerjee, MD, FACP from Fred Hutch Cancer Center talks on #Cevostamab: A “third-party candidate” in myeloma? ✅ FcRH5 target, maintained post-BCMA exposure ✅ Manageable safety, fewer infections vs. BCMA bsAbs ✅ No GPRC5D toxicities ⏳ Needs better efficacy/durability! #DAVAWhistler

We call for a paradigm shift in development of immunotherapy drugs, especially bispecifics. Leukemia Journal These drugs have therapeutic effects that last a long time. We need to reduce frequency and switch to limited duration treatment to avoid toxicity. nature.com/articles/s4137…

Early results in patients who had failed prior CAR T: → 81% overall response → 52% complete remission at 3 months → 3-day manufacturing turnaround This research from Carl June and team represents the first IL-18–secreting CAR T tested in blood cancer — and it may reshape

Happy to share our new work out today on Blood Journals Portfolio #Blood where we report CD38 loss as recurrent mechanisms of resistance to anti-CD38 antibody in multiple myeloma. Great collaboration between Memorial Sloan Kettering Cancer Center MSK Department of Medicine U Calgary Heidelberg Myeloma Mayo Clinic #mmsm #wgs

Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group [Jun 18, 2025] Lu et al. Linda B. Baughn Blood Cancer Journal nature.com/articles/s4140… #mmsm #hemepath